Assistência Farmacêutica e governança global da saúde em tempos de Covid-19

Ribeiro, Alane Andrelino; Ricardi, Luciani Martins; Pontes, Marcela Amaral; Leite, Silvana Nair

doi:10.1590/0103-1104202213318

Acessibilidade / Reportar erro

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

ENSAIO • Saúde debate 46 (133) • Apr-Jun 2022 • https://doi.org/10.1590/0103-1104202213318 copiar

Assistência Farmacêutica e governança global da saúde em tempos de Covid-19

Autoria SCIMAGO INSTITUTIONS RANKINGS

RESUMO

Este ensaio aborda como e em que níveis a Assistência Farmacêutica é atravessada pela dinâmica da governança global da saúde, e como se relaciona com aspectos geopolíticos e socioeconômicos. Tenta-se ir além do acesso a medicamentos e produtos para saúde, abordando também o uso racional de medicamentos, seu impacto na resistência aos antimicrobianos e na saúde dos povos. Além disso, discute como a Assistência Farmacêutica pode ser vista nesse contexto.

PALAVRAS-CHAVE
Assistência Farmacêutica; Saúde global; Covid-19

Tema	Documento
Direitos de propriedade intelectual, inovação e saúde pública	WHO. World Health Assembly. WHA 56.27. Intellectual property rights, innovation and public health Resolution. WHA 28 May 2003. WHO. World Health Assembly. WHA61.21. Global strategy and plan of action on public health, innovation and intellectual property. 2008. http://mobile.wpro.who.int/health_research/policy_documents/global_strategy_may2008.pdf WHO. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. 2011. https://www.who.int/phi/publications/Global_Strategy_Plan_Action.pdf WHO. World Health Assembly. WHA68.18: Global strategy and plan of action on public health, innovation and intellectual property. 2015. WHO. World Health Assembly. WHA69.23: Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination. 2016. WHO. World Health Assembly. WHA71.9: Global strategy and plan of action on public health, innovation and intellectual property: overall programme review. 2017. WHO. World Health Assembly. WHA71.13: Global strategy and plan of action on public health, innovation and intellectual property: overall programme review. 2018. WHO. World Health Assembly. Resolution WHA73.1: COVID-19 response. 2020. https://apps.who.int/gb/ebwha/pdf_fi-les/WHA73/A73_R1-en.pdf
Expansão do acesso a medicamentos e outras tecnologias	UN. united Nations General Assembly. Resolution UN A/RES/74/274. Resolution adopted by the General Assembly on 20 April 2020. International cooperation to ensure global access to medicines, vaccines and medical equipment to face COVID-19. 2020. https://undocs.org/en/A/RES/74/274 UN. united Nations General Assembly. Resolution UN S/RES/2565 (2021). Resolution adopted by the General Assembly on 26 February 2021. 2021. https://undocs.org/en/S/RES/2565(2021) WHO. World Health Assembly. WHA70.12: Cancer prevention and control in the context of an integrated approach. 2017. WHO. World Health Assembly. WHA71.8: Addressing the global shortage of, and access to, medicines and vaccines. 2018. WHO. World Health Organization. Roadmap for access to medicines, vaccines and health products 2019-2023: comprehensive support for access to medicines, vaccines and other health products. 2019a. ISbN 9789241517034. https://apps.who.int/iris/handle/10665/330145 WHO. Executive board. Report Eb 148/9. Expanding access to effective treatments for cancer and rare and orphan diseases, including medicines, vaccines, medical devices, diagnostics, assistive products, cell- and gene-based therapies and other health technologies; and improving the transparency of markets for medicines, vaccines, and other health products. 2020. https://apps.who.int/gb/ebwha/pdf_files/Eb148/b148_9-en.pdf WHO. World Health Organization. Resolution WHA73.1: COVID-19 response. 2020. https://apps.who.int/gb/ebwha/pdf_files/WHA73/A73_R1-en.pdf OEA. CP/doc. 5673/21 rev. 2. Organización de los Estados Americanos. Draft Resolution - The Equitable Distribution of Covid-19 Vaccines. http://www.oas.org/es/council/CP/documentation/var_documents/cpdoc/
Preços de medicamentos	WHO. World Health Organization. Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly. 2018. https://apps.who.int/iris/handle/10665/277190?show=full WHO. World Health Organization. WHO guideline on country pharmaceutical pricing policies. 2020. ISbN: 9789240011878 https://www.who.int/publications-detail-redirect/9789240011878 WHO. World Health Organization. Fair pricing of medicines. 2021. https://www.who.int/medicines/access/fair_pricing/en/
Fortalecimento da produção local de medicamentos e outras tecnologias para saúde	WHO. World Health Organization. Resolution WHA 74.6. Strengthening local production of medicines and other health technologies to improve access Draft resolution proposed by China, Eswatini, Ethiopia, Ghana, Kenya, Namibia, Rwanda, South Africa, Sudan, Togo and Zimbabwe. 2021. https://apps.who.int/gb/ebwha/pdf_files/Eb148/b148_CONF9-en.pdf
Fortalecimento da transparência do mercado farmacêutico e de outras tecnologias para saúde	WHO. World Health Organization. Resolution WHA 72.8. Improving the transparency of markets for medicines, vaccines, and other health products. 2019. https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R8-en.pdf WHO. Executive board. Report Eb 148/9. Expanding access to effective treatments for cancer and rare and orphan diseases, including medicines, vaccines, medical devices, diagnostics, assistive products, cell- and gene-based therapies and other health technologies; and improving the transparency of markets for medicines, vaccines, and other health products. 2020. https://apps.who.int/gb/ebwha/pdf_files/Eb148/b148_9-en.pdf

Centro Brasileiro de Estudos de Saúde Av. Brasil, 4036, sala 802, 21040-361 Rio de Janeiro - RJ Brasil, Tel. 55 21-3882-9140, Fax.55 21-2260-3782 - Rio de Janeiro - RJ - Brazil
E-mail: revista@saudeemdebate.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Colaboradoras

Ribeiro AA (0000-0003-0233-9465)^* * Orcid (Open Researcher and Contributor ID). contribuiu para concepção, planejamento, análise e interpretação dos dados; revisão do texto do artigo e aprovação da versão final do manuscrito. Ricardi LM (0000-0002-7500-0465)^* * Orcid (Open Researcher and Contributor ID). contribuiu para análise e interpretação dos dados e revisão do texto do artigo. Pontes MA (0000-0002-0726-7475)^* * Orcid (Open Researcher and Contributor ID). contribuiu para análise e interpretação dos dados e revisão do texto do artigo. Leite SN (0000-0002-5258-9684)^* * Orcid (Open Researcher and Contributor ID). contribuiu para o planejamento, revisão do texto do artigo e aprovação da versão final do manuscrito. ■